All In Biotech

Drug Trial Radar · NCT07931573

AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Semaglutide s.c. Once Weekly at Higher Dose Levels in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2i, or Both (AMBITION 3)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Nov 10, 2026

Primary completion

Jul 4, 2028

Study completion Aug 8, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will get one of the following: Zenagamtide (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator).

Conditions

  • Type 2 Diabetes

Interventions

  • ZenagamtideDrug

    Zenagamtide will be administered subcutaneously

  • SemaglutideDrug

    Semaglutide will be administered subcutaneously

  • PlaceboDrug

    Placebo matched to semaglutide or zenagamtide will be administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in glycated haemoglobin (HbA1c) [non-inferiority]Time frame: From baseline (week 0) to week 60

Locations

230 sites in 22 countries. Site status is shown where the registry gives one.

  • Rio Clinical Trials Arizona

    Phoenix, Arizona

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • Diabetes & Endocrine Specialists - La Mesa

    La Mesa, California

  • First Valley Med Grp Lancaster

    Lancaster, California

  • Los Angeles Institute for Metabolic Research

    Los Angeles, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • Linda Vista Health Care Ctr

    San Diego, California

  • Southern Cal Clinical Research

    Santa Ana, California

  • Encompass Clinical Research_Spring Valley

    Spring Valley, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Chase Medical Research LLC

    Waterbury, Connecticut

  • Encore Medical Research LLC

    Hollywood, Florida

  • University of Florida Cardiology

    Jacksonville, Florida

  • My Preferred Research

    Miami, Florida

  • New Horizon Research Center

    Miami, Florida

  • GTL Med & Res Group

    Miami, Florida

  • Life Medical Research Group

    Miami Gardens, Florida

  • South Broward Research LLC

    Miramar, Florida

  • Adult Medicine of Lake County, Inc

    Mt. Dora, Florida

  • West Orange Endocrinology

    Ocoee, Florida

  • Florida Institute for Clinical research

    Orlando, Florida

  • True Blue Clinical Research

    Tampa, Florida

  • Encore Medical Research of Weston

    Weston, Florida

  • Solaris Clinical Research

    Meridian, Idaho

  • Clinical Invest Special_Gurnee

    Gurnee, Illinois

  • Cotton O'Neil Diab & Endo Ctr

    Topeka, Kansas

  • MedStar Health Research Institute

    Olney, Maryland

  • Endo And Metab Cons

    Rockville, Maryland

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • Elite Clinical Research

    Flint, Michigan

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • Palm Research Center Inc-Vegas

    Las Vegas, Nevada

  • Southern NH Diabetes and Endo_Nashua

    Nashua, New Hampshire

  • AMC Community Endocrinology

    Albany, New York

  • Southgate Medical Group, LLP

    West Seneca, New York

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina

  • Monroe Biomedical Research, LLC

    Monroe, North Carolina

  • Accellacare

    Wilmington, North Carolina

  • Diab & Endo Assoc of Stark Co

    Canton, Ohio

Showing 40 of 230 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.